Incyte Corporation (INCY) Net Profit Margin: 26.71%
Is Incyte Corporation’s net profit margin high or low?
Incyte Corporation's net profit margin of 26.71% is 121% above its 5-year average of 12.11%, near the high end of its 5-year range (-11.09%–31.76%).
As of Sunday, June 21, 2026. 107.05% above its 12-month average of 12.90%.
INCY Net Profit Margin Chart
INCY Average Net Profit Margin Chart
INCY Current vs Average Net Profit Margin Chart
INCY Net Profit Margin Metrics
NET PROFIT MARGIN
26.71%
NET PROFIT MARGIN AVG TTM
12.90%
NET PROFIT MARGIN AVG 3Y
13.00%
NET PROFIT MARGIN AVG 5Y
12.11%
NET PROFIT MARGIN AVG 10Y
8.10%
NET PROFIT MARGIN AVG 15Y
1.50%
NET PROFIT MARGIN AVG 20Y
-38.64%
CURRENT VS TTM AVG
+107.05%
CURRENT VS 3Y AVG
+105.42%
CURRENT VS 5Y AVG
+120.50%
CURRENT VS 10Y AVG
+229.68%
CURRENT VS 15Y AVG
+1677.51%
CURRENT VS 20Y AVG
+169.13%
INCY Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 26.71% | 12.90% | 13.00% | 12.11% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 6.66% | 6.01% | 6.56% | 9.24% |
| Viatris Inc. (VTRS)vs › | $17.90B | -2.04% | -14.44% | -3.94% | -4.74% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 9.05% | 10.17% | 9.38% | 6.86% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 40.61% | 41.73% | 40.84% | 37.71% |
| BioNTech SE (BNTX)vs › | $22.98B | -44.73% | -31.89% | 3.77% | 12.08% |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 21.40% | 21.94% | 21.74% | 21.20% |
| Waters Corporation (WAT)vs › | $23.17B | 11.91% | 20.93% | 21.85% | 22.39% |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 28.37% | 27.22% | 24.83% | 24.72% |
Margin Comparison
Operating Margin
27.1%
Net Profit Margin
26.7%
Incyte Corporation Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Net Profit Margin FAQ
- What is the net profit margin for Incyte Corporation (INCY)?
- The net profit margin for INCY stock is 26.71%.
- Is Incyte Corporation's net profit margin high or low?
- Incyte Corporation's net profit margin of 26.71% is 121% above its 5-year average of 12.11%, near the high end of its 5-year range (-11.09%–31.76%).
- What is the TTM average net profit margin for Incyte Corporation (INCY)?
- The TTM average net profit margin for INCY stock is 12.90%.
- What is the 3Y average net profit margin for Incyte Corporation (INCY)?
- The 3Y average net profit margin for INCY stock is 13.00%.
- What is the 5Y average net profit margin for Incyte Corporation (INCY)?
- The 5Y average net profit margin for INCY stock is 12.11%.
- What is the 10Y average net profit margin for Incyte Corporation (INCY)?
- The 10Y average net profit margin for INCY stock is 8.10%.
- What is the 15Y average net profit margin for Incyte Corporation (INCY)?
- The 15Y average net profit margin for INCY stock is 1.50%.
- What is the 20Y average net profit margin for Incyte Corporation (INCY)?
- The 20Y average net profit margin for INCY stock is -38.64%.
Incyte Corporation Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 25.03% |
| 2024-12-31 | 0.77% |
| 2023-12-31 | 16.17% |
| 2022-12-31 | 10.04% |
| 2021-12-31 | 31.76% |
| 2020-12-31 | -11.09% |
| 2019-12-31 | 20.70% |
| 2018-12-31 | 5.82% |
| 2017-12-31 | -20.38% |
| 2016-12-31 | 9.43% |
| 2015-12-31 | 0.87% |
| 2014-12-31 | -9.48% |
| 2013-12-31 | -23.43% |
| 2012-12-31 | -14.92% |
| 2011-12-31 | -197.49% |
| 2010-12-31 | -18.75% |
| 2009-12-31 | -2286.78% |
| 2008-12-31 | -4565.45% |
| 2007-12-31 | -252.27% |
| 2006-12-31 | -268.30% |
| 2005-12-31 | -1313.32% |
| 2004-12-31 | -1165.11% |
| 2003-12-31 | -404.07% |
| 2002-12-31 | -143.38% |
| 2001-12-31 | -83.57% |
| 2000-12-31 | -15.31% |
| 1999-12-31 | -17.07% |
| 1998-12-31 | 2.60% |
| 1997-12-31 | 7.67% |
| 1996-12-31 | -16.23% |
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury